Primary study · included by 1 review
Effect of recombinant human thyroid‐stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation
Iakovou 2016 · Iakovou Ioannis, Goulis Dimitrios G., Tsinaslanidou Zinovia, et al. · Head & Neck · 2015
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · within 2 months after RIT | Prevalence 0.60 [0.28, 0.85] | 3 studies · 1502 participants | GRADE not reported |
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · between 2 and 6 months after RIT | Prevalence 0.37 [0.28, 0.47] | 4 studies · 392 participants | GRADE not reported |
1 including review in total.